Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
38 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Niemann Pick C1 Like Protein 1 (NPC1L1) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Niemann Pick C1 Like Protein 1 (NPC1L1) - Pipeline Review, H1 2016', provides in depth analysis on Niemann Pick C1 Like Protein 1 (NPC1L1) targeted pipeline therapeutics. The report provides comprehensive information on the Niemann Pick C1 Like Protein 1 (NPC1L1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Niemann Pick C1 Like Protein 1 (NPC1L1) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Niemann Pick C1 Like Protein 1 (NPC1L1) - The report reviews Niemann Pick C1 Like Protein 1 (NPC1L1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Niemann Pick C1 Like Protein 1 (NPC1L1) targeted therapeutics and enlists all their major and minor projects - The report assesses Niemann Pick C1 Like Protein 1 (NPC1L1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Niemann Pick C1 Like Protein 1 (NPC1L1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Niemann Pick C1 Like Protein 1 (NPC1L1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Niemann Pick C1 Like Protein 1 (NPC1L1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Niemann Pick C1 Like Protein 1 (NPC1L1) Overview 6 Therapeutics Development 7 Niemann Pick C1 Like Protein 1 (NPC1L1) - Products under Development by Stage of Development 7 Niemann Pick C1 Like Protein 1 (NPC1L1) - Products under Development by Therapy Area 8 Niemann Pick C1 Like Protein 1 (NPC1L1) - Products under Development by Indication 9 Niemann Pick C1 Like Protein 1 (NPC1L1) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Niemann Pick C1 Like Protein 1 (NPC1L1) - Products under Development by Companies 12 Niemann Pick C1 Like Protein 1 (NPC1L1) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 17 Niemann Pick C1 Like Protein 1 (NPC1L1) - Companies Involved in Therapeutics Development 18 Alvogen Korea Co., Ltd. 18 Chong Kun Dang Pharmaceutical Corp. 19 CJ HealthCare Corp. 20 Esperion Therapeutics, Inc. 21 Kotobuki Pharmaceutical Co., Ltd. 22 Merck & Co., Inc. 23 Zhejiang Hisun Pharmaceutical Co., Ltd. 24 Niemann Pick C1 Like Protein 1 (NPC1L1) - Drug Profiles 25 (atorvastatin calcium + ezetimibe) - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 (atorvastatin calcium + ezetimibe) - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 (bempedoic acid + ezetimibe) - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 (ezetimibe + rosuvastatin calcium) - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 (ezetimibe + rosuvastatin calcium) - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 (ezetimibe + rosuvastatin calcium) - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 HS-25 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 KT-6971 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Niemann Pick C1 Like Protein 1 (NPC1L1) - Dormant Projects 33 Niemann Pick C1 Like Protein 1 (NPC1L1) - Featured News & Press Releases 34 Feb 15, 2016: Merck Receives Complete Response Letter from the U.S. FDA for ZETIA (ezetimibe) 34 Jan 14, 2014: Merck Voluntarily Recalls All Lots of LIPTRUZET in the United States From Wholesalers Due to Packaging Defects 35 May 03, 2013: Merck Gets FDA Approval For Liptruzeta For Treatment Of Primary Or Mixed Hyperlipidemia 35 Jan 02, 2013: Merck Announces FDA Acknowledgement Of Resubmission Of New Drug Application For Ezetimibe/Atorvastatin Tablets 35 Apr 04, 2012: Frontage Successfully Files IND To Launch US Statin Study 36 Nov 03, 2009: FDA Turns Down Merck's Application For Combo Cholesterol Pill Involving Lipitor 36 Mar 27, 2007: Merck And Schering To Develop Zetia/Lipitor Combo As Focus On Reducing Bad Cholesterol Returns 36 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 37 Disclaimer 38
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Action, H1 2016 15 Number of Products by Stage and Route of Administration, H1 2016 16 Number of Products by Stage and Molecule Type, H1 2016 17 Pipeline by Alvogen Korea Co., Ltd., H1 2016 18 Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 19 Pipeline by CJ HealthCare Corp., H1 2016 20 Pipeline by Esperion Therapeutics, Inc., H1 2016 21 Pipeline by Kotobuki Pharmaceutical Co., Ltd., H1 2016 22 Pipeline by Merck & Co., Inc., H1 2016 23 Pipeline by Zhejiang Hisun Pharmaceutical Co., Ltd., H1 2016 24 Dormant Projects, H1 2016 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
